The estimated mortality impact of vaccinations forecast to be administered during 2011-2020 in 73 countries supported by the gavi alliance

Vaccine

Volumn 31, Issue SUPPL2, 2013, Pages

  Lee, Lisa A ^a   Franzel, Lauren ^b   Atwell, Jessica ^c   Datta, S Deblina ^d   Friberg, Ingrid K ^c   Goldie, Sue J ^e,f   Reef, Susan E ^g   Schwalbe, Nina ^d   Simons, Emily ^h   Strebel, Peter M ^h   Sweet, Steven ^f   Suraratdecha, Chutima ^b   Tam, Yvonne ^c   Vynnycky, Emilia ⁱ   Walker, Neff ^c   Walker, Damian G ^j   Hansen, Peter M ^d  

^a medical consultant   (United States)

^b PATH   (United States)

^c JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^d GAVI Alliance   (Switzerland)

^e HARVARD UNIVERSITY   (United States)

^f HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^g CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^h WORLD HEALTH ORGANIZATION   (Switzerland)

ⁱ PUBLIC HEALTH ENGLAND   (United Kingdom)

^j BILL AND MELINDA GATES FOUNDATION   (United States)

more..

Author keywords

Developing countries; Immunization; Impact; Mortality

Indexed keywords

HAEMOPHILUS INFLUENZAE TYPE B VACCINE; HEPATITIS B VACCINE; JAPANESE ENCEPHALITIS VACCINE; MEASLES VACCINE; MENINGOCOCCUS VACCINE; PNEUMOCOCCUS VACCINE; ROTAVIRUS VACCINE; RUBELLA VACCINE; WART VIRUS VACCINE; YELLOW FEVER VACCINE;

AFRICA; AGE DISTRIBUTION; ENDEMIC DISEASE; HAEMOPHILUS INFECTION; HAEMOPHILUS INFLUENZAE TYPE B; HEALTH CARE ACCESS; HEALTH IMPACT ASSESSMENT; HEPATITIS B; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; INFECTION CONTROL; JAPANESE ENCEPHALITIS; MATHEMATICAL MODEL; MEASLES; MENINGOCOCCOSIS; MORTALITY; OUTCOME ASSESSMENT; PAPILLOMAVIRUS INFECTION; PNEUMOCOCCAL INFECTION; PRIORITY JOURNAL; PUBLIC HEALTH; REVIEW; ROTAVIRUS INFECTION; RUBELLA; SOUTHEAST ASIA; SOUTHERN EUROPE; VACCINATION; YELLOW FEVER;

COMMUNICABLE DISEASE CONTROL; HUMANS; MODELS, THEORETICAL; MORTALITY; VACCINATION; WORLD HEALTH;

EID: 84876707923     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.11.035     Document Type: Review

References (81)

1. Applied Strategies GAVI vaccine portfolio metrics analysis. Input assumptions - board paper case. Unpublished presentation at the GAVI Board Meeting 2009.
2. Lee L.A. Forecasting the impact of GAVI Alliance vaccine support using the long range cost and impact model: methods and limitations August 9, 2011, GAVI Consultant Report.
3. United Nations, Department of Economic and Social Affairs, Population Division World population prospects, the 2010 revision 2010, Available at: http://esa.un.org/wpp/Excel-Data/mortality.htm.
4. Global Vaccine Action Plan. Vaccine 2013, 31:B5-B31. Decade of Vaccines Collaboration.
5. World Health Organization and United Nations Children's Fund Immunization summary January 2012, United Nations Children's Fund, New York. 2012 edition.
6. Goldstein S.T., Zhou F., Hadler S.C., Bell B.P., Mast E.E., Margolis H.S. A mathematical model to estimate global hepatitis B disease burden and vaccination impact. Int J Epidemiol 2005, 34:1329-1339.
7. Winfrey W., McKinnon R., Stover J. Methods used in the Lives Saved Tool (LiST). BMC Public Health 2011, 11(Suppl. 3):S32.
8. Watt J.P., Wolfson L.J., O'Brien K.L., Henkle E., Deloria-Knoll M., McCall N., et al. Burden of disease caused by Haemophilus influenzae type b in children younger than 5 years: global estimates. Lancet 2009, 374:903-911.
9. Theodoratou E., Johnson S., Jhass A., Madhi S.A., Clark A., Boschi-Pinto C., et al. The effect of Haemophilus influenzae type b and pneumococcal conjugate vaccines on childhood pneumonia incidence, severe morbidity and mortality. Int J Epidemiol 2010, 39(Suppl. 1):i172-i185.
10. Black R.E., Cousens S., Johnson H.L., Lawn J.E., Rudan I., Bassani D.G., et al. Global, regional, and national causes of child mortality in 2008: a systematic analysis. Lancet 2010, 375:1969-1987.
11. Morris S.S., Black R.E., Tomaskovic L. Predicting the distribution of under-five deaths by cause in countries without adequate vital registration systems. Int J Epidemiol 2003, 32:1041-1051.
12. O'Brien K.L., Wolfson L.J., Watt J.P., Henkle E., Deloria-Knoll M., McCall N., et al. Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates. Lancet 2009, 374:893-902.
13. Boschi-Pinto C., Velebit L., Shibuya K. Estimating child mortality due to diarrhoea in developing countries. Bull World Health Organ 2008, 86:710-717.
14. Parashar U.D., Gibson C.J., Bresee J.S., Glass R.I. Rotavirus and severe childhood diarrhea. Emerg Infect Dis 2006, 12:304-306.
15. Fischer Walker C.L., Black R.E. Rotavirus vaccine and diarrhea mortality: quantifying regional variation in effect size. BMC Public Health 2011, 11(Suppl. 3):S16.
16. Richardson V., Hernandez-Pichardo J., Quintanar-Solares M., Esparza-Aguilar M., Johnson B., Gomez-Altamirano C.M., et al. Effect of rotavirus vaccination on death from childhood diarrhea in Mexico. N Engl J Med 2010, 362:299-305.
17. do Carmo G.M., Yen C., Cortes J., Siqueira A.A., de Oliveira W.K., Cortez-Escalante J.J., et al. Decline in diarrhea mortality and admissions after routine childhood rotavirus immunization in Brazil: a time-series analysis. PLoS Med 2011, 8:e1001024.
18. Goldie S.J., O'Shea M., Campos N.G., Diaz M., Sweet S., Kim S. Health and economic outcomes of HPV 16,18 vaccination in 72 GAVI-eligible countries. Vaccine 2008, 26:4080-4093.
19. Kim J.J., Kuntz K.M., Stout N.K., Mahmud S., Villa L.L., Franco E.L., et al. Multiparameter calibration of a natural history model of cervical cancer. Am J Epidemiol 2007, 166:137-150.
20. Goldie S.J., Kim J.J., Kobus K., Goldhaber-Fiebert J.D., Salomon J., O'Shea M.K., et al. Cost-effectiveness of HPV 16 18 vaccination in Brazil. Vaccine 2007, 25:6257-6270.
21. Kim J.J., Andres-Beck B., Goldie S.J. The value of including boys in an HPV vaccination programme: a cost-effectiveness analysis in a low-resource setting. Br J Cancer 2007, 97:1322-1328.
22. Goldie S.J., Gaffikin L., Goldhaber-Fiebert J.D., Gordillo-Tobar A., Levin C., Mahé C., et al. Cost-effectiveness of cervical cancer screening in five developing countries. N Engl J Med 2005, 353:2158-2168.
23. Goldie S.J., Diaz M., Constenla D., Alvis N., Andrus J.K., Kim S.Y. Mathematical models of cervical cancer prevention in Latin America and the Caribbean. Vaccine 2008, 26:L59-L72.
24. Goldie S.J., Diaz M., Kim S.Y., Levin C.E., Minh H.V., Kim J.J. Mathematical models of cervical cancer prevention in the Asia Pacific region. Vaccine 2008, 26:M17-M29.
25. Campos N.G., Kim J.J., Castle P.E., Ortendahl J.D., O'Shea M., Diaz M., et al. Health and economic impact of HPV 16/18 vaccination and cervical cancer screening in Eastern Africa. Int J Cancer 2012, 130:2672-2684.
26. Diaz M., Kim J.J., Albero G., de Sanjosé S., Clifford G., Bosch F.X., et al. Health and economic impact of HPV 16 and 18 vaccination and cervical cancer screening in India. Br J Cancer 2008, 99:230-238.
27. Kim S.Y., Goldie S.J. Cost-effectiveness analyses of vaccination programmes: a focused review of modelling approaches. Pharmacoeconomics 2008, 26:191-215.
28. Ferlay J., Shin H.R., Bray F., Forman D., Mathers C., Parkin D.M. GLOBOCAN 2008, Cancer incidence and mortality worldwide. IARC Cancer Base No. 10 [Internet] 2010, International Agency for Research on Cancer, Lyon, Available at: http://globocan.iarc.fr.
29. de Sanjose S., Quint W.G., Alemany L., Geraets D.T., Klaustermeier J.E., Lloveras B., et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol 2010, 11:1048-1056.
30. Gakidou E., Nordhagen S., Obermeyer Z. Coverage of cervical cancer screening in 57 countries: low average levels and large inequalities. PLoS Med 2008, 5:e132.
31. Howlader N., NooneAM, Krapcho M., Neyman N., Aminou R., Altekruse S.F., et al. SEER cancer statistics review, 1975-2009 (vintage 2009 populations) 2009, National Cancer Institute, Bethesda, MD, Available at: http://seer.cancer.gov/csr/1975_2009_pops09/.
32. Monath T.P., Nasidi A. Should yellow fever vaccine be included in the expanded program of immunization in Africa? A cost-effectiveness analysis for Nigeria. Am J Trop Med Hyg 1993, 2:274-299.
33. World Health Organization and United Nations Children's Fund Eliminating serogroup A meningococcal meningitis epidemics as a public health problem in Africa. An investment case for the GAVI Alliance May 2008.
34. Campagne G., Schuchat A., Djibo S., Ousséini A., Cissé L., Chippaux J.P. Epidemiology of bacterial meningitis in Niamey, Niger, 1981-96. Bull World Health Organ 1999, 77:499-508.
35. Touch S., Suraratdecha C., Samnang C., Heng S., Gazley L., Huch C., et al. A cost-effectiveness analysis of Japanese encephalitis vaccine in Cambodia. Vaccine 2010, 28:4593-4599.
36. Suraratdecha C., Jacobson J., Sivalenka S., Narahari D. A cost-effectiveness analysis of strategies for controlling Japanese encephalitis in Andhra Pradesh, India. J Pharm Finance Econ Pol 2006, 15:21-40.
37. Campbell G.L., Hills S.L., Fischer M., Jacobson J.A., Hoke C.H., Hombach J.M., et al. Estimated global incidence of Japanese encephalitis: a systematic review. Bull World Health Organ 2011, 89:766-774.
38. Kari K., Liu W., Gautama K., Mammen M.P., Clemens J.D., Nisalak A., et al. A hospital-based surveillance for Japanese encephalitis in Bali, Indonesia. BMC Med 2006, 7(4):8.
39. Sohn Y.M. Japanese encephalitis immunization in South Korea: past present and future. Emerg Infect Dis 2000, 6:17-24.
40. Solomon T., Dung N.M., Kneen R., Gainsborough M., Vaughn D.W., Khanh V.T. Japanese encephalitis. J Neurol Neurosurg Psychiatr 2000, 68:405-415.
41. Tandan J.B., Ohrr H., Sohn Y.M., Yoksan S., Ji M., Nam C.M., et al. Single dose of SA 14-14-2 vaccine provides long-term protection against Japanese encephalitis: a case-control study in Nepalese children 5 years after immunization. Vaccine 2007, 25:5041-5045.
42. Cutts F.T., Vynnycky E. Modelling the incidence of congenital rubella syndrome in developing countries. Int J Epidemiol 1999, 28:1176-1184.
43. Vynnycky E., Gay N.J., Cutts F.T. The predicted impact of private sector MMR vaccination on the burden of congenital rubella syndrome. Vaccine 2003, 21:2708-2719.
44. Gilks W.R., Richardson S., Spiegelhalter D. Markov chain Monte Carlo in practice 1995, Chapman & Hall, CRC Interdisciplinary Statistics, CRC Press, Boca Raton.
45. Miller E., Cradock-Watson J.E., Pollock T.M. Consequences of confirmed maternal rubella at successive stages of pregnancy. Lancet 1982, 2:781-784.
46. Al-Awaidy S., Griffiths U.K., Nwar H.M., Bawikar S., Al-Aisiri M.S., Khandekar R., et al. Costs of congenital rubella syndrome (CRS) in Oman: evidence based on long-term follow-up of 43 children. Vaccine 2006, 24:6437-6445.
47. Lawn J.E., Reef S., Baffoe-Bonnie B., Adadevoh S., Caul E.O., Griffin G.E. Unseen blindness, unheard deafness, and unrecorded death and disability: congenital rubella in Kumasi Ghana. Am J Public Health 2000, 90:1555-1561.
48. Saad de Owens C., Tristan de Espino R. Rubella in Panama: still a problem. Pediatr Infect Dis J 1989, 8:110-115.
49. Lanzieri T.M., Pinto D., Prevots D.R. Impact of rubella vaccination strategy on the occurrence of congenital rubella syndrome. J Pediatr 2007, 83:415.
50. Chen S., Fricks J., Ferrari M.J. Tracking measles infection through non-linear state space models. Appl Stat 2012, 61:117-134.
51. Simons E., Ferrari M., Fricks J., Wannemuehler K., Anand A., Burton A., et al. Assessment of the 2010 global measles mortality reduction goal: results from a model of surveillance data. Lancet 2012, 379:2173-2178.
52. Stein C.E., Birmingham M., Kurian M., Duclos P., Strebel P. The global burden of measles in the year 2000-a model that uses country-specific indicators. J Infect Dis 2003, 187(Suppl. 1):S8-S14.
53. Uzicanin A., Zimmerman L. Field effectiveness of live attenuated measles-containing vaccines: a review of published literature. J Infect Dis 2011, 204(Suppl. 1):S133-S148.
54. Wolfson L.J., Grais R.F., Luquero F.J., Birmingham M.E., Strebel P.M. Estimates of measles case fatality ratios: a comprehensive review of community-based studies. Int J Epidemiol 2009, 38:192-205.
55. Brenzel L., Wolfson L.J., Fox-Rushby J., Miller M., Halsey N.A. Vaccine-preventable diseases. Disease control priorities in developing countries 2006, 389-411. Oxford University Press/The World Bank, Washington, DC. 2nd ed. B. Jamison, A. Measham, E. Claeson, M. Jha, Musgrove (Eds.).
56. Crump J.A., Luby S.P., Mintz E.D. The global burden of typhoid fever. Bull World Health Organ 2004, 82:346-353.
57. Lin F.Y., Ho V.A., Khiem H.B., Trach D.D., Bay P.V., Thanh T.C., et al. The efficacy of a Salmonella typhi Vi conjugate vaccine in two-to-five-year-old children. N Engl J Med 2001, 344:1263-1269.
58. Mai N.L., Phan V.B., Vo A.H., Tran C.T., Lin F.Y., Bryla D.A., et al. Persistent efficacy of Vi conjugate vaccine against typhoid fever in young children. N Engl J Med 2003, 349:1390-1391.
59. Sur D., Lopez A.L., Kanungo S., Paisley A., Manna B., Ali M., et al. Efficacy and safety of a modified killed whole-cell oral cholera vaccine in India: an interim analysis of a cluster-randomised double-blind, placebo-controlled trial. Lancet 2009, 374:1694-1702.
60. Trach D.D., Clemens J.D., Ke N.T., Thuy H.T., Son N.D., Canh D.G., et al. Field trial of a locally produced, killed, oral cholera vaccine in Vietnam. Lancet 1997, 349:231-235.
61. Agnandji S.T., Lell B., Soulanoudjingar S.S., Fernandes J.F., Abossolo B.P., Conzelmann C., et al. First results of phase 3 trial of RTS, S/AS01 malaria vaccine in African children. N Engl J Med 2011, 365:1863-1875.
62. Patel M.M., Steele D., Gentsch J.R., Wecker J., Glass R.I., Parashar U.D. Real-world impact of rotavirus vaccination. Pediatr Infect Dis J 2011, 30(Suppl. 1):S1-S5.
63. Gessner B.D., Sutanto A., Linehan M., Djelantik I.G., Fletcher T., Gerudug I.K., et al. Incidences of vaccine-preventable Haemophilus influenzae type b pneumonia and meningitis in Indonesian children: hamlet-randomised vaccine-probe trial. Lancet 2005, 365:43-52.
64. Novak R.T., Kambou J.L., Diomandé F.V., Tarbangdo T.F., Ouédraogo-Traoré R., Sangaré L., et al. Serogroup A meningococcal conjugate vaccination in Burkina Faso: analysis of national surveillance data. Lancet Infect Dis 2012, 12:757-764.
65. Clark A., Sanderson C. Timing of children's vaccinations in 45 low-income and middle-income countries: an analysis of survey data. Lancet 2009, 373:1543-1549.
66. Orenstein W.A., Bernier R.H., Hinman A.R. Assessing vaccine efficacy in the field: further observations. Epidemiol Rev 1988, 10:212-241.
67. Cherian T., Mulholland E.K., Carlin J.B., Ostensen H., Amin R., de Campo M., et al. Standardized interpretation of paediatric chest radiographs for the diagnosis of pneumonia in epidemiological studies. Bull World Health Organ 2005, 83:353-359.
68. Cherian T. Describing the epidemiology and aetiology of bacterial pneumonia in children: an unresolved problem. J Health Popul Nutr 2005, 23:1-5.
69. Gessner B.D. Acute lower respiratory infection in the developing world. Expert Rev Respir Med 2011, 5:459-463.
70. Murray C.J., Lopez A.D., Wibulpolprasert S. Monitoring global health: time for new solutions. BMJ 2004, 329:1096-1100.
71. Liu L., Johnson H.L., Cousens S., Perin J., Scott S., Lawn J.E., et al. Global, regional, and national causes of child mortality: an updated systematic analysis for 2010 with time trends since 2000. Lancet 2012, 379:2151-2161.
72. Williams B.G., Gouws E., Boschi-Pinto C., Bryce J., Dye C. Estimates of world-wide distribution of child deaths from acute respiratory infections. Lancet Infect Dis 2002, 2:25-32.
73. Rani M., Yang B., Nesbit R. Hepatitis B control by 2012 in the WHO Western Pacific Region: rationale and implications. Bull World Health Organ 2009, 87:707-713.
74. Cui F.Q., Gong X.H., Chen Y.S., Wang F.Z., Zheng H., Hu Y.S., et al. Evaluation of the impact of hepatitis B vaccine integration into routine immunization in the areas of the Ministry of Health/Global Alliance for Vaccines and Immunizations (GAVI) Cooperation Project, People's Republic of China. Zhongguo Yi Miao He Mian Yi 2009, 15:289-293. [in Chinese].
75. Soeung S.C., Rani M., Huong V., Sarath S., Kimly C., Kohei T. Results from nationwide hepatitis B serosurvey in Cambodia using simple and rapid laboratory test: implications for national immunization program. Am J Trop Med Hyg 2009, 81:252-257.
76. Gessner B.D. Haemophilus influenzae type b vaccine impact in resource-poor settings in Asia and Africa. Expert Rev Vaccines 2009, 8:91-102.
77. Lee E.H., Corcino M., Moore A., Garib Z., Peña C., Sánchez J., et al. Impact of Haemophilus influenzae type b conjugate vaccine on bacterial meningitis in the Dominican Republic. Pan Am J Public Health 2008, 24:161-168.
78. Lopman B.A., Payne D.C., Tate J.E., Patel M.M., Cortese M.M., Parashar U.D. Post-licensure experience with rotavirus vaccination in high and middle income countries; 2006 to 2011. Curr Opin Virol 2012, 2:434-442.
79. World Health Organization Global measles and rubella strategic plan, 2012-2020 2012, World Health Organization, Geneva.
80. LaForce F.M., Okwo-Bele J.M. Eliminating epidemic Group A meningococcal meningitis in Africa through a new vaccine. Health Aff (Millwood) 2011, 30:1049-1057.
81. World Health Organization Global plan of action for new and under-utilized vaccines implementation: 2010-2011 July 28, 2010, World Health Organization, Geneva.